Prophylaxis of erectile function after radical prostatectomy with phosphodiesterase type 5 inhibitors.
Erectile dysfunction (ED) is one of the most challenging complications associated with radical prostatectomy (RP) for clinically localized prostate cancer. Currently, a broad spectrum of therapeutic options are available to improve sexual health after surgical treatment. Several basic science reports highlighted a potential role for phosphodiesterase type 5 inhibitors in the prevention of endothelial damage related to ischemia reperfusion and/or denervation following surgery. Recent studies have shown that pharmacological prophylaxis soon after RP can significantly improve the rate at which erectile function is recovered after surgery. Use of on-demand treatments for ED in patients who have undergone RP has been shown to be highly effective. In this context, pharmacological prophylaxis potentially may have a significantly expanded role in future strategies aimed at preserving postoperative erectile function. We analyzed the factors affecting erectile function after RP and evaluated the evidence suggesting the role of pharmacological prophylaxis and treatment of ED after surgery.
Deho
F
F
Department of Urology, Vita-Salute University, Milan, Italy.
Gallina
A
A
Salonia
A
A
Briganti
A
A
Suardi
N
N
Zanni
G
G
Guazzoni
G
G
Rigatti
P
P
Montorsi
F
F
D007172:Erectile Dysfunction / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000209:etiology* / Q000517:prevention & control*; D011468:Prostatectomy
D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors